A candidate precursor to serous carcinoma that originates in the distal fallopian tube - PubMed (original) (raw)
A Miron, R Drapkin, M R Nucci, F Medeiros, A Saleemuddin, J Garber, C Birch, H Mou, R W Gordon, D W Cramer, F D McKeon, C P Crum
Affiliations
- PMID: 17117391
- DOI: 10.1002/path.2091
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Y Lee et al. J Pathol. 2007 Jan.
Erratum in
- J Pathol. 2007 Sep;213(1):116
Abstract
The tubal fimbria is a common site of origin for early (tubal intraepithelial carcinoma or TIC) serous carcinomas in women with familial BRCA1 or 2 mutations (BRCA+). Somatic p53 tumour suppressor gene mutations in these tumours suggest a pathogenesis involving DNA damage, p53 mutation, and progressive loss of cell cycle control. We recently identified foci of strong p53 immunostaining-termed 'p53 signatures'-in benign tubal mucosa from BRCA+ women. To examine the relationship between p53 signatures and TIC, we compared location (fimbria vs ampulla), cell type (ciliated vs secretory), evidence of DNA damage, and p53 mutation status between the two entities. p53 signatures were equally common in non-neoplastic tubes from BRCA+ women and controls, but more frequently present (53%) and multifocal (67%) in fallopian tubes also containing TIC. Like prior studies of TIC, p53 signatures predominated in the fimbriae (80-100%) and targeted secretory cells (HMFG2 + /p73-), with evidence of DNA damage by co-localization of gamma-H2AX. Laser-capture microdissected and polymerase chain reaction-amplified DNA revealed reproducible p53 mutations in eight of 14 fully-analysed p53 signatures and all of the 12 TICs; TICs and their associated ovarian carcinomas shared identical mutations. In one case, a contiguous p53 signature and TIC shared the same mutation. Morphological intermediates between the two, with p53 mutations and moderate proliferative activity, were also seen. This is the first report of an early and distinct alteration in non-neoplastic upper genital tract mucosa that fulfils many requirements for a precursor to pelvic serous cancer. The p53 signature and its malignant counterpart (TIC) underline the significance of the fimbria, both as a candidate site for serous carcinogenesis and as a target for future research on the early detection and prevention of this disease.
Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
Similar articles
- Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. Kindelberger DW, et al. Am J Surg Pathol. 2007 Feb;31(2):161-9. doi: 10.1097/01.pas.0000213335.40358.47. Am J Surg Pathol. 2007. PMID: 17255760 - Precursors to pelvic serous carcinoma and their clinical implications.
Folkins AK, Jarboe EA, Roh MH, Crum CP. Folkins AK, et al. Gynecol Oncol. 2009 Jun;113(3):391-6. doi: 10.1016/j.ygyno.2009.01.013. Epub 2009 Feb 23. Gynecol Oncol. 2009. PMID: 19237187 Review. - p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn LC. Leonhardt K, et al. Int J Gynecol Pathol. 2011 Sep;30(5):417-24. doi: 10.1097/PGP.0b013e318216d447. Int J Gynecol Pathol. 2011. PMID: 21804388 - Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer.
Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Lee Y, et al. Adv Anat Pathol. 2006 Jan;13(1):1-7. doi: 10.1097/01.pap.0000201826.46978.e5. Adv Anat Pathol. 2006. PMID: 16462151 Review. - Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ. Rabban JT, et al. Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7. Am J Surg Pathol. 2009. PMID: 18830124
Cited by
- Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Chen X, et al. Hum Pathol. 2013 Nov;44(11):2373-84. doi: 10.1016/j.humpath.2013.05.001. Epub 2013 Jul 11. Hum Pathol. 2013. PMID: 23850493 Free PMC article. Review. - Fallopian tube single cell analysis reveals myeloid cell alterations in high-grade serous ovarian cancer.
Brand J, Haro M, Lin X, Rimel BJ, McGregor SM, Lawrenson K, Dinh HQ. Brand J, et al. iScience. 2024 Jan 23;27(3):108990. doi: 10.1016/j.isci.2024.108990. eCollection 2024 Mar 15. iScience. 2024. PMID: 38384837 Free PMC article. - Genetic and molecular changes in ovarian cancer.
Hollis RL, Gourley C. Hollis RL, et al. Cancer Biol Med. 2016 Jun;13(2):236-47. doi: 10.20892/j.issn.2095-3941.2016.0024. Cancer Biol Med. 2016. PMID: 27458531 Free PMC article. - Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.
Vang R, Visvanathan K, Gross A, Maambo E, Gupta M, Kuhn E, Li RF, Ronnett BM, Seidman JD, Yemelyanova A, Shih IeM, Shaw PA, Soslow RA, Kurman RJ. Vang R, et al. Int J Gynecol Pathol. 2012 May;31(3):243-53. doi: 10.1097/PGP.0b013e31823b8831. Int J Gynecol Pathol. 2012. PMID: 22498942 Free PMC article. - Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Casey MJ, Bewtra C, Lynch HT, Snyder C, Stacy M, Watson P. Casey MJ, et al. Fam Cancer. 2013 Dec;12(4):719-40. doi: 10.1007/s10689-013-9651-x. Fam Cancer. 2013. PMID: 23666231
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous